Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
On July 8, 2026, Avacta Therapeutics, a clinical stage biopharmaceutical company focusing on developing pre|CISION® - a tumor-activated oncology delivery platform, announced the appointment of Dr. Patrick Vink as Non-Executive Deputy Chairman and Senior Independent Director to its Board of Directors. Dr. Vink, a seasoned healthcare executive, will bring his expertise to the Company. AVCT (AIM) saw a positive response to this news, with a notable increase in its stock value following the announcement.